Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

Gamida Cell receives Breakthrough Therapy Designation from FDA

October 12, 2016 Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma

Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …
News
transgene

Transgene announce key partnership with Merck KGaA and Pfizer

October 12, 2016 Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck

Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …
News

NICE backs Celgene’s Otezla for psoriatic arthritis

October 12, 2016 Research and Development, Sales and Marketing Celgene, NICE, otezla

The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …
News
astrazeneca_logo_building

AstraZeneca forced to abandon Phase II trial

October 12, 2016 Research and Development AstraZeneca, Synairgen, asthma, cold, common cold

Synairgen, a respiratory drug discovery and development company, has developed a drug, AZD9412, alongside AstraZeneca to treat and prevent severe …
News
aaeaaqaaaaaaaaiyaaaajgqxy2rmmzrlltrhmzktndzhns05mza3lwmwmjliywjmzdu5zg

Sanofi appoint Alan Main to Executive Committee and Executive Vice President Consumer Healthcare

October 11, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Sanofi announced the appointment of Alan Main as Executive Vice President Consumer Healthcare effective October 1.Mr Main, who previously worked …
Appointment
exelixis_hq_web

Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

October 11, 2016 Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …
News
takeda_world

Takeda enters $790m cancer development deal

October 11, 2016 Manufacturing and Production, Research and Development Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody

Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …
News
teva-kim-innes-250

New UK & Ireland general manager for Teva

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment

Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …
Appointment
shutterstock_142740349_resize_3

Educating pharma

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency

Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …
Feature
opdivo_1_1

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016 Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
News
roche__tree

Roche’s lung cancer success spells competition for BMS’ Opdivo

October 10, 2016 Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq

Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …
News

“Incorrect classification” of EpiPen leads to $1 billion bill for US government

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal

Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …
News
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
News
alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
News
basel_site

Novartis axes 175 jobs globally in operations reshuffle

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026